Arca
Skip to content
Tools
Tools

DNA-directed RNA polymerase

Complex in Escherichia coli that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Genes: 4

Who is on it, and how far along

Every drug ChEMBL records acting on RPOA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Rifamycin

Phase 31

  • Rifalazil

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      RifamycinApprovedCosmo PharmaceuticalsSmall moleculeInhibitorDNA-directed RNA polymerase inhibitor100
      RifalazilPhase 3ActivBioticsSmall moleculeInhibitorDNA-directed RNA polymerase inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without LevofloxacinRifamycinPhase 3RecruitingTuberculosis Research Centre, IndiaNov 18, 2026
      Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial)RifamycinPhase 2Not yet recruitingFondation Raoul FollereauNov 5, 2026
      Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated BrucellosisRifamycinNot applicableNot yet recruitingThe First Affiliated Hospital of Shihezi UniversityOct 21, 2026
      All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular BrucellosisRifamycinNot applicableNot yet recruitingThe First Affiliated Hospital of Shihezi UniversityOct 21, 2026
      SIMBA in Irritable Bowel Syndrome (IBS)RifamycinPhase 1Not yet recruitingUniversity of CalgaryOct 20, 2026
      A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11RifamycinPhase 1RecruitingGates Medical Research InstituteOct 20, 2026
      A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080RifamycinPhase 1Not yet recruitingShandong Suncadia Medicine Co., Ltd.Oct 15, 2026
      A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy AdultsRifamycinPhase 1Not yet recruitingInventisBio Co., LtdOct 15, 2026

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4296169, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.